350 rub
Journal №12 for 2011 г.
Article in number:
Biochemical Markers in Diagnostics and Treatment of Neuroendocrine Tumors (Review)
Keywords: neuroendocrine tumor molecular markers diagnostics treatment screening
Authors:
A.A. Markovich, N.F. Orel, N.V. Lubimova
Abstract:
Neuroendocrine tumors (NET) may affect different organs and show a great variety of symptoms. The main common feature of this tumor type is an ability to produce biologically active substances (hormones, vasoactive peptides), determining the vast majority of clinical manifestations. NET was supposed to be rare tumors and it took a long time to summarize clinical materials and elaborate the modern conception of NET nature. Several reassessments were necessary to identify these tumors as a separate group and classify them properly. Recently developed advanced diagnostic methods allow revealing the dynamics of basic NET markers (chromogranin A, neurospecific enolase, serotonin etc.) thus significantly widening screening, diagnostic and treatment options, resulting in better quality of life and survival rates in NET patients. The review presents main events in NET conception development as well as modern terms and classifications, symptoms and syndromes related to overproduction of biologically active substances. The most important NET markers, their clinical significance, and use of somatostatin analogs for functional tumors treatment are described in the paper.
Pages: 28-37
References
  1. Heidenhain R. Untersuchungen uber den bau der labdrusen // Arch. Mirk. Anat. 1870. V. 6. P. 368.
  2. Kulchitsky N. Zur Frage uber den Bau des Darmkanals // Arch. Mikr. Anat. 1897. № 49.
  3. Williams E., Sandler M. The classification of carcinoid tumors // Lancet. 1963. V. 1. P. 238-239.
  4. Pearse A.G. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept // J. Histochem. Cynochem. 1969. V. 17. P. 303-313.
  5. Knowles F. Neuroendocrine correlations at the level of ultrastructure // Arch Anat Microsc Morphol Exp. 1965. V. 54. P. 343-357.
  6. Soga J., Tazawa K. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases // Cancer. 1971. V. 28. P. 990-998.
  7. Solcia E., Kloppe1 G., Sobin L. Histological Typing of Endocrine Tumours: WHO International Histological Classification of Tumours. 2000. Springer. Berlin.
  8. Klimstra D.S., Modlin I.R., Coppola D., Lloyd R.V., Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems // Pancreas. 2010. V. 39. № 6. P. 707-12.
  9. Modlin I., Lye K., Kidd M. A 5-decade analysis of 13715 carcinoid tumors // Cancer. 2003. V. 97. P. 934-959.
  10. Kaltsas G.A., Besser G.M., Grossman A.B. The diagnosis and medical management of advanced neuroendocrine tumors // Endocrinol. Rev. 2004. V. 25. P. 458-511.
  11. Janson E, Holmberg L, Stritsberg M et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center // Ann. Oncol. 1997. V. 8. P. 685-690
  12. Falconi M., Bettini R., Scarpa A. et al. Surgical strategy in the treatment of gastrointestinal neuroendocrine tumours // Ann. Oncol. 2001. V. 12. (Suppl. 2). P. 101-103.
  13. Oberg K., Kvols L., Caplin M., Delle Fave G., De Hender W., Rindi G., Rusniewski P., Woltering E. A., Wiedenmann B. Treatment of neuroendocrine GEP tumours with somatostatin analogues // Ann. Oncol. 2004. V. 15. P. 966-973.
  14. Modlin I., Kidd M., Latich I. et al. Current status of gastrointestinal carcinoids // Gastroenterology. 2005. V. 128. P. 1717-1751.
  15. Lesurtel M., Soll C., Graf R., Clavien P.A. Role of serotonin in the gepato-gastrointestinal tract: an old molecule for new perspectives // Cell Moll. Life Sci. 2008. V. 65. P. 940-952.
  16. Пальцев М.А., Кветной И.М. Руководство по нейроиммуноэндокринологии. М. Медицина. 2008. C. 79.
  17. Jian B. et al. Serotonin mechanisms in heart valve disease i: serotonin-induced upregulation of transforming growth factor beta1 via G-protein signal transduction in aortic valve interstitial cells // Am. J. Pathol. 2002. V. 161. P. 2111-2121.
  18. Moller J.E. et al. Factors associated with progression of carcinoid heart disease // N. Engl. J. Med. 2003. V. 348. P. 1005-1015.
  19. Woodart P.K., Feldman J.M., Paine S.S., Baker M.E. Midgaut carcinoid tumors: CT findings and biochemical profiles // J. Comput. Assist. Tomogr. 1995. V. 19. P. 400-405.
  20. Caplin M.E. et al. Carcinoid. tumor // Lancet. 1998. V. 352. P. 799-805.
  21. Kulke M.H., Mayer R.J. Carcinoid tumors // N. Engl. J. Med. 1999. V. 340. P. 858-868.
  22. Bhattacharyya S., Davar J., Dreyfus G., Caplin M.E. Сarcinoid heart disease // Circulation. 2007. V. 116. P. 2860-2865.
  23. Bhattaharyya S., Toumpanakis C., Caplin M.E., Davar J. Usefulness of n-terminal pro-brain natriuretic peptide as a biomarker of the presense of carcinoid heart disease // Am. J. Cardiol. 2008. V. 102. P. 938-942.
  24. Oberg K., Stridsberg M. Neuroendocrine tumors / In: Tumor Markers / eds. E.P. Diamandis, H.A. Fritsche, H. Lilija et al. AACC Press. Washington DC. 2002. P. 339-349.
  25. Modlin I. M., Sandor A. An analysis of 8305 cases of carcinoid tumors // Cancer. 1997. V. 79. P. 813-829.
  26. Янкин А.В. Нейроэндокринные опухоли желудочно-кишечного тракта // Практическая онкология. 2005. № 4. С. 227-233.
  27. Brazeau P., Vale W., Burgus R. et al. Hypothalamic polypeptide that inhibit the secretion of immunoreactive pituitary grows hormone // Scienes. 1973. V. 179. P. 77-79.
  28. Симоненко В.Б., Дулин П.А., Маканин М.А. Карциноиды и нейроэндокринные опухоли. М. Медицина. 2008. C. 144.
  29. Reubi J., Wasser B., Schaer J. et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands // Eur. J. Nucl. Med. 2001. V. 28. P. 836-846.
  30. Ohrvall U. et al. Method for dissection of mesenteric metastases in midgut carcinoid tumors // World J. Surg. 2000. V. 24. P. 1402-1408.